Tenderwize
Retour à la recherche

Open-House Biologics Discount Agreements 2025-20 - Pegfilgrastim

Techniker Krankenkasse·Hamburg, Germany·Deadline Aug 30, 2027 · 369 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-20 - Pegfilgrastim

50/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

40 / 100

Facteurs de risque

The procedure is explicitly not a public procurement under EU directives; therefore, standard procurement remedies are...

Open House allows any eligible participant, potentially resulting in many competitors and high price pressure.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Conclusion of pharmaceutical discount agreements for Pegfilgrastim under §130a(8) SGB V.
  • Open-House procedure: any eligible pharmaceutical entrepreneur can participate.
Afficher le résumé complet

Open House procedure for concluding discount agreements (Rabattverträge) under §130a(8) SGB V for the active substance Pegfilgrastim. Any qualified pharmaceutical entrepreneur can join during the contract period (01.09.2025 – 31.08.2027). No exclusivity, no negotiated terms; uniform conditions apply.

Risques

The procedure is explicitly not a public procurement under EU directives; therefore, standard procurement remedies are...

Open House allows any eligible participant, potentially resulting in many competitors and high price pressure.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur according to §4(18) AMG regarding the offered medicinal product.
  • Must have a valid marketing authorization for the drug (§21 AMG) or be otherwise entitled to market it.
  • Seat must be in Germany, another EU member state, or an EEA state.

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open-House Biologics Discount Agreements 2025-20 - Pegfilgrastim

Conclusion of discount agreements for the active substance Pegfilgrastim via Open-House procedure. Open to all eligible pharmaceutical entrepreneurs during the contract period.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Aug 2025 - Aug 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Aug 30, 2027

Détails de la procédure

Date de publication
16 Jul 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
468072-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3